薬理と治療

Abstract

Objectives The aim of this study was to evaluate the effect of continuous 4-week ingestion of tablets containing lactotripeptides（Val-Pro-Pro, VPP; Ile-Pro-Pro, IPP）on lassitude in young healthy people. Methods We conducted a randomized, double-blind, placebo-controlled trial in healthy male university students who exercise regularly. The subjects were randomly divided into test or placebo groups. They ingested tablets containing lactotripeptides（VPP, 2.5 mg; IPP, 3.7 mg）or placebo continuously for 4 weeks. Lassitude as assessed using a visual analog scale（VAS）was set as the primary endpoint, while muscle pain assessed using VAS as well as lassitude, muscle pain, and blood creatine kinase activity assessed using a multiple-choice questionnaire were set as secondary endpoint. Results Lassitude increased significantly in both groups 4 weeks after treatment as compared to that before treatment（test group, P＜0.05; placebo group, P＜0.01）; however, the test group exhibited a significantly lower lassitude after 4 weeks of treatment than that of the placebo group（P＜0.01）. Furthermore, while no significant change in muscle pain was observed in the test group, it increased significantly in the placebo group（P＜0.01）. Conclusions These results indicate that 4 weeks of continuous ingestion of tablets containing lactotripeptides is a beneficial for reduction of lassitude in healthy, young people who exercise regularly.